ATE409487T1 - Behandlung von morbus parkinson mit oligonukleotiden - Google Patents
Behandlung von morbus parkinson mit oligonukleotidenInfo
- Publication number
- ATE409487T1 ATE409487T1 AT99971323T AT99971323T ATE409487T1 AT E409487 T1 ATE409487 T1 AT E409487T1 AT 99971323 T AT99971323 T AT 99971323T AT 99971323 T AT99971323 T AT 99971323T AT E409487 T1 ATE409487 T1 AT E409487T1
- Authority
- AT
- Austria
- Prior art keywords
- parkinson
- disease
- treatment
- oligonucleotides
- targeted
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 5
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 5
- 208000018737 Parkinson disease Diseases 0.000 title abstract 4
- 108091022930 Glutamate decarboxylase Proteins 0.000 abstract 3
- 230000000692 anti-sense effect Effects 0.000 abstract 3
- 210000004556 brain Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000003828 downregulation Effects 0.000 abstract 2
- 210000001905 globus pallidus Anatomy 0.000 abstract 2
- 210000003523 substantia nigra Anatomy 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 102000005915 GABA Receptors Human genes 0.000 abstract 1
- 108010005551 GABA Receptors Proteins 0.000 abstract 1
- 102000018899 Glutamate Receptors Human genes 0.000 abstract 1
- 108010027915 Glutamate Receptors Proteins 0.000 abstract 1
- 102000008214 Glutamate decarboxylase Human genes 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 230000000542 thalamic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
- C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10719198P | 1998-11-05 | 1998-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE409487T1 true ATE409487T1 (de) | 2008-10-15 |
Family
ID=22315323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99971323T ATE409487T1 (de) | 1998-11-05 | 1999-11-05 | Behandlung von morbus parkinson mit oligonukleotiden |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20030060436A1 (de) |
| EP (1) | EP1135113B1 (de) |
| JP (1) | JP2002528509A (de) |
| AT (1) | ATE409487T1 (de) |
| CA (1) | CA2350212A1 (de) |
| DE (1) | DE69939663D1 (de) |
| ES (1) | ES2317710T3 (de) |
| WO (1) | WO2000025798A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003259073A1 (en) * | 2002-08-07 | 2004-02-25 | University Of Delaware | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
| ES2266432T3 (es) * | 2002-12-13 | 2007-03-01 | Centre National De La Recherche Scientifique (Cnrs) | Procedimiento para el diagnostico de la obesidad. |
| KR100616742B1 (ko) * | 2004-02-27 | 2006-08-28 | 한국원자력연구소 | 글루타메이트 디카르복실라제 67의 안티센스 유전자를유효성분으로 포함하는 항암제, 상기 유전자를 포함하는발현 벡터 및 이를 형질도입한 형질전환체 |
| WO2006013457A2 (en) * | 2004-03-19 | 2006-02-09 | Diamyd Medical Ab | Gad2 gene for possible treatment of nervous system disorders |
| TWI809004B (zh) * | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
| CN120310791A (zh) | 2018-01-12 | 2025-07-15 | 百时美施贵宝公司 | 靶向α-突触核蛋白的反义寡核苷酸及其用途 |
| US12241065B2 (en) | 2018-01-12 | 2025-03-04 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| WO2020210634A1 (en) | 2019-04-11 | 2020-10-15 | Enclear Therapies, Inc. | Methods of amelioration of cerebrospinal fluid and devices and systems therefor |
| IL301751A (en) | 2020-09-29 | 2023-05-01 | Enclear Therapies Inc | Subarachnoid fluid management method and system |
| EP4359054A4 (de) * | 2021-06-23 | 2025-06-25 | Enclear Therapies, Inc. | Verfahren zur regulierung der genexpression |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU678769B2 (en) * | 1992-07-27 | 1997-06-12 | Hybridon, Inc. | Oligonucleotide alkylphosphonothioates |
| US5929042A (en) * | 1997-03-03 | 1999-07-27 | The Trustees Of Columbia University In The City Of New York | Antisense compounds which prevent cell death and uses thereof |
-
1999
- 1999-11-05 AT AT99971323T patent/ATE409487T1/de not_active IP Right Cessation
- 1999-11-05 CA CA002350212A patent/CA2350212A1/en not_active Abandoned
- 1999-11-05 DE DE69939663T patent/DE69939663D1/de not_active Expired - Lifetime
- 1999-11-05 WO PCT/US1999/026128 patent/WO2000025798A1/en not_active Ceased
- 1999-11-05 ES ES99971323T patent/ES2317710T3/es not_active Expired - Lifetime
- 1999-11-05 JP JP2000579238A patent/JP2002528509A/ja active Pending
- 1999-11-05 US US09/435,249 patent/US20030060436A1/en not_active Abandoned
- 1999-11-05 EP EP99971323A patent/EP1135113B1/de not_active Expired - Lifetime
-
2004
- 2004-09-09 US US10/937,824 patent/US7414034B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20050020530A1 (en) | 2005-01-27 |
| ES2317710T3 (es) | 2009-04-16 |
| EP1135113B1 (de) | 2008-10-01 |
| US20030060436A1 (en) | 2003-03-27 |
| US7414034B2 (en) | 2008-08-19 |
| JP2002528509A (ja) | 2002-09-03 |
| WO2000025798A8 (en) | 2002-01-17 |
| EP1135113A4 (de) | 2004-12-22 |
| CA2350212A1 (en) | 2000-05-11 |
| WO2000025798A1 (en) | 2000-05-11 |
| DE69939663D1 (de) | 2008-11-13 |
| EP1135113A1 (de) | 2001-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69939663D1 (de) | Behandlung von morbus parkinson mit oligonukleotiden | |
| Wallace et al. | The amygdalo-brainstem pathway: selective innervation of dopaminergic, noradrenergic and adrenergic cells in the rat | |
| Sessle | Neural mechanisms and pathways in craniofacial pain | |
| Scharfman et al. | Actions of brain-derived neurotrophic factor in slices from rats with spontaneous seizures and mossy fiber sprouting in the dentate gyrus | |
| Nutt | Pharmacokinetics and pharmacodynamics of levodopa | |
| US5885976A (en) | Methods useful for the treatment of neurological and mental disorders related to deficient serotonin neurotransmission and impaired pineal melatonin functions | |
| Dishman | The norepinephrine hypothesis | |
| EP2139475B1 (de) | PDE7-Inhibitoren zur Verwendung bei der Behandlung von Bewegungsstörungen | |
| WO1992011851A1 (en) | Method and compositions for treatment of sexual impotence | |
| ATE207352T1 (de) | Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen | |
| Peng et al. | Involvement of alpha-2 adrenoceptors in the periaqueductal gray-induced inhibition of dorsal horn cell activity in rats. | |
| Da Prada et al. | The effect of 5, 6-dihydroxytryptamine on sexual behaviour of male rats | |
| Duty et al. | Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression | |
| Lefaucheur | Repetitive transcranial magnetic stimulation (rTMS): insights into the treatment of Parkinson’s disease by cortical stimulation | |
| DE69935331D1 (de) | Verfahren und verbindungen zur behandlung der depression | |
| Hanalioglu et al. | Cortical spreading depression can be triggered by sensory stimulation in primed wild type mouse brain: a mechanistic insight to migraine aura generation | |
| Hamani et al. | Deep brain stimulation for the treatment of Parkinson’s disease | |
| Gnanalingham et al. | Chronic continuous and intermittentl-3, 4-dihydroxyphenylalanine treatments differentially affect basal ganglia function in 6-hydroxydopamine lesioned rats—an autoradiographic study using [3H] flunitrazepam | |
| BOSHES | Sinemet and the treatment of parkinsonism | |
| JP2002528509A5 (de) | ||
| Lees | Levodopa substitution: the gold standard | |
| BR0307345A (pt) | Métodos para tratar disfunção erétil, para melhorar a microcirculação da glans penis e para produzir intumescência da glans penis em um paciente necessitando de tais tratamentos, artigo de manufatura, e, composição | |
| CA2525524A1 (en) | Combination of the analeptic modafinil and an antidepressant for the treatment of depression | |
| Meissner et al. | Impact of chronic subthalamic high‐frequency stimulation on metabolic basal ganglia activity: a 2‐deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease | |
| Ogura et al. | The mechanism and effect of chronic electrical stimulation of the globus pallidus for treatment of Parkinson disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |